Evofem signs manufacturing deal to cut PHEXXI cost ~55-60%; extends merger close to Sept 2025 with $1.5M investment

Evofem Biosciences, Inc.

Windtree to manufacture PHEXXI; Evofem expects COGS reduction of 55-60%.
No cost to Evofem for tech transfer; Windtree engaged a manufacturer.
Fifth Amendment extends merger consummation date to Sept 30, 2025.
Aditxt must invest $1.5M by April 7, 2025 via F-1 preferred or notes.
Evofem to use best efforts to hold shareholder meeting by Sept 26, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.